Literature DB >> 26922560

Anticancer agent 3-bromopyruvic acid forms a conjugate with glutathione.

Izabela Sadowska-Bartosz1, Rafal Szewczyk2, Lukasz Jaremko3, Mariusz Jaremko4, Grzegorz Bartosz5.   

Abstract

BACKGROUND: 3-Bromopyruvic acid (3-BP), a glycolytic inhibitor and a promising anticancer compound, induces oxidative stress and depletes cells of glutathione (GSH). The causes of GSH loss remain unclear. The aim of this study was to ascertain whether 3-BP forms a conjugate with glutathione.
METHODS: GSH was incubated with various amounts of 3-BP and the extent of reaction was titrated with (1)H NMR and (1)H-(1)H NMR. The reaction outcome was identified by MS/MS. Intracellular formation of the conjugate was assessed in cells treated with 3-BP and 3-BP((13)C) and analyzed using the targeted LC-MS/MS method in negative ionization MRM mode.
RESULTS: 3-BP was found to react with GSH in a 1:1 ratio forming an S-conjugate. The same conjugate was formed intracellularly in erythrocytes and MCF-7 cells.
CONCLUSIONS: 3-BP reacts with GSH in the absence of cells and intracellularly. This reaction appears to be the main cause of GSH loss in 3-BP treated cells.
Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  3-Bromopyruvate; Erythrocyte; Glutathione; Mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 26922560     DOI: 10.1016/j.pharep.2015.11.007

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  7 in total

1.  3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.

Authors:  Minjong Lee; Ara Jo; Seulki Lee; Jong Bin Kim; Young Chang; Joon Yeul Nam; Hyeki Cho; Young Youn Cho; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Jung-Hwan Yoon; Yoon Jun Kim
Journal:  PLoS One       Date:  2017-03-31       Impact factor: 3.240

Review 2.  Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment.

Authors:  Tengjiao Fan; Guohui Sun; Xiaodong Sun; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2019-03-06       Impact factor: 6.639

3.  Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-Bromopyruvate.

Authors:  Natalia Pieńkowska; Grzegorz Bartosz; Paulina Furdak; Izabela Sadowska-Bartosz
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

4.  3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation.

Authors:  Irini Skaripa-Koukelli; David Hauton; John Walsby-Tickle; Eloïse Thomas; Joshua Owen; Abirami Lakshminarayanan; Sarah Able; James McCullagh; Robert C Carlisle; Katherine A Vallis
Journal:  Cancer Metab       Date:  2021-10-14

Review 5.  Glutathione-Mediated Conjugation of Anticancer Drugs: An Overview of Reaction Mechanisms and Biological Significance for Drug Detoxification and Bioactivation.

Authors:  Agnieszka Potęga
Journal:  Molecules       Date:  2022-08-17       Impact factor: 4.927

6.  The Anticancer Drug 3-Bromopyruvate Induces DNA Damage Potentially Through Reactive Oxygen Species in Yeast and in Human Cancer Cells.

Authors:  Magdalena Cal; Irwin Matyjaszczyk; Ireneusz Litwin; Daria Augustyniak; Rafał Ogórek; Young Ko; Stanisław Ułaszewski
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

7.  Construction and Evaluation of Folic Acid-Modified 3-Bromopyruvate Cubosomes.

Authors:  Fangyan Hou; Hairong Wang; Yawen Zhang; Na Zhu; Hao Liu; Jianchun Li
Journal:  Med Sci Monit       Date:  2020-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.